ACCELERATING INNOVATION IN NK CELL THERAPY
Dead / Abandoned — Abandoned — no statement of use filed (as of 11 Jul 2022)
What this means for you
This application is over — abandoned 11 Jul 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88048416
- Mark type
- Stylized text
- Filed
- 23 Jul 2018
- Published for opposition
- 09 Apr 2019
- Abandoned
- 11 Jul 2022
- Attorney of record
- Karen Lim
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of immuno oncological disorders, cancer, diabetes, respiratory, heart, neurological and auto immune disorders; stem cells for medical purposes; living cells for medical use; biological preparations for the treatment of cancer; therapeutic pharmaceuticals utilizing neural crest cells for use in the treatment of cancer, autoimmune disease and infectious diseases; Cell preparations, cellular vaccines and cellular biologics for the treatment of cancer and infectious diseases by autologous cell-based immunotherapy
- Class 042 — Scientific and technological services: Scientific and technological services, namely, scientific research, design, analysis and testing in the field of cancer evolution and new cancer therapies using natural killer cells; industrial research in the field of new pharmaceutical products and new cancer therapies; medical and veterinary research services in the nature of the manipulation of cells within a laboratory or research facility to enable natural killer cells to be used for medical or therapeutic purposes; scientific research in the development of new cancer therapies; scientific research in human and animal cell therapy; scientific research into preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services; Conducting research and clinical trials for others relating to the use and the engineering of natural killer cells and cancer treatment and therapy; medical and scientific research in the field of cancer treatment and diagnosis; data collection for others for research purposes, namely, the collection, testing and research of patient molecular and genomic data; collection and preservation of human and animal DNA for research purposes
- Class 044 — Medical, beauty and agricultural services: Medical testing for diagnostic or treatment purposes in the field of cancer research; medical diagnostic testing, monitoring and reporting services; medical evaluation of immuno oncological disorders, cancer, diabetes, respiratory, heart, neurological and auto immune disorders; medical monitoring services; medical diagnostic, prognostic and theranostic screening and testing services; collection and preservation of dna for medical purposes; consulting services in the nature of providing medical information; consulting services in the field of healthcare and cancer diagnoses; providing a website featuring health and healthcare information related to cancer, testing and screening; genetic testing for medical purposes; providing information in the field of cancer prevention, screening, diagnosis and treatment for medical diagnostic and treatment purposes; providing genetics assessments in the nature of genetic counseling; genetic testing for medical diagnostic purposes; genomic testing for medical diagnostic purposes; Gene analysis and sequencing and DNA analysis and sequencing for medical diagnostic purposes and veterinary diagnostics purposes; gene analysis and sequencing and DNA analysis and sequencing for use in cancer diagnosis and treatment; providing a website featuring health and healthcare information related to cancer research
Owner
- KIADIS PHARMA INTELLECTUAL PROPERTY B.V., AMSTERDAM, NL
- CytoSen Therapeutics, Inc., Winter Springs, FL, US
- CytoSen Therapeutics, Inc., Winter Springs, FL, US
Prosecution history
- 11 Jul 2022 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 11 Jul 2022 — ABANDONMENT - NO USE STATEMENT FILED
- 01 Dec 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 30 Nov 2021 — SOU EXTENSION 5 GRANTED
- 22 Nov 2021 — SOU EXTENSION 5 FILED
- 30 Nov 2021 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 22 Nov 2021 — SOU TEAS EXTENSION RECEIVED
- 17 Nov 2021 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 17 Nov 2021 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 17 Nov 2021 — TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
- 17 Nov 2021 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 17 Nov 2021 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 17 Nov 2021 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 17 Nov 2021 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 20 May 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED